Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOOSTERS - Biologics in Folliculitis Decalvans
2024-514848-88-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in Folliculitis decalvans (FD) comparing Adalimumab monotherapy, Ustekinumab monotherapy and Baricitinib monotherapy (3 arms). Primary endpoint: FD-IGA response at 6 months. Planned start Nov 2025; status: authorised.
02
Drugs
03
Conditions
Folliculitis decalvans (FD)
Beyond the preview
Go deeper on 2024-514848-88-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514848-88-00.